系统综述与荟萃分析:皮肤不良事件在索拉非尼治疗肝细胞癌患者中的关键作用
该系统综述与荟萃分析检索截至2018年10月的原始文献,纳入13项研究共2035例接受索拉非尼治疗的肝细胞癌患者,评估皮肤不良事件与预后的关联。皮肤不良事件发生率为47.7%(手足皮肤反应)与31.7%(其他类型),其出现与较低死亡率相关(未调整HR 0.45,95%CI 0.38-0.53;无异质性,P=0.511;I²=0.0%)。作者认为该关联具有临床意义,支持将皮肤不良事件用于预后告知与系统治疗决策。
要点
- 索拉非尼治疗肝细胞癌患者中,皮肤不良事件出现与较低死亡率相关(未调整HR 0.45,95%CI 0.38-0.53)。
- 皮肤不良事件主要为手足皮肤反应(47.7%),其他皮肤不良事件占31.7%。
- 作者认为该关联有临床意义,支持将皮肤不良事件用于预后告知与系统治疗决策。
核心结论
- 该荟萃分析显示皮肤不良事件与更长生存概率之间存在有临床意义的关联。
- 这些数据支持在告知预后及决定系统治疗时使用皮肤不良事件进行临床决策。
研究设计与样本
- 系统检索PubMed/MEDLINE截至2018年10月发表的原始文章,并按PRISMA声明进行荟萃分析。
- 共识别393项研究,最终纳入13篇文章、2035例患者(79.5%为Child-Pugh-A级,73.2%为BCLC-C期)进行定性与定量分析。
主要发现
- 主要皮肤不良事件类型为手足皮肤反应(47.7%),其他皮肤不良事件报告于31.7%的病例。
- 出现皮肤不良事件的患者与未出现者相比死亡率较低(未调整分析合并HR 0.45,95%CI 0.38-0.53)。
- 该分析无异质性(P=0.511;I²=0.0%)。
- 推翻该关联需要未来报告1370项阴性研究。
临床怎么用
- 作者认为皮肤不良事件可用于预后告知及系统治疗决策时的临床决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The positive results of the REFLECT trial in terms of survival (sorafenib vs lenvatinib) offer a new first-line option for hepatocellular carcinoma. Additionally, the expected results of immunotherapy could change the first-line treatment in hepatocellular carcinoma or the clinical trial design in first and second-line. AIMS: To evaluate the impact of dermatologic adverse events under sorafenib in hepatocellular carcinoma patients as a clinical marker to predict prognosis and critically evaluate outcomes within trials. METHODS: A systematic search of original articles published until October 2018 was performed using PubMed/MEDLINE and a meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. RESULTS: A total of 393 studies were identified and 13 articles with 2035 patients (79.5% Child-Pugh-A, 73.2% BCLC-C) were selected for qualitative and quantitative analysis. The main type of dermatologic adverse events was hand-foot skin reaction (47.7%) but other dermatologic adverse events were reported in 31.7% of the cases. Presence of dermatologic adverse events was associated with a lower mortality when compared with those patients without them (pooled Hazard Ratio for the univariate analysis 0.45 (95% CI: 0.38-0.53) and there was no heterogeneity for the analysis (P = 0.511; I2 = 0.0%). Refuting this association would require the future report of 1370 negative studies. CONCLUSIONS: This meta-analysis shows a clinically meaningful association between dermatologic adverse events and a higher probability of longer survival. These data support the use of dermatologic adverse events in the clinical decision-making when informing the prognosis and when systemic treatment is decided.
引用
- Díaz-González Á, Sanduzzi-Zamparelli M, Sapena V, et al. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther. 2019. PMID: 30695819. doi:10.1111/apt.15088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。